Eli Lilly will begin offering vials of its best-selling weight-loss drug Zepbound through Ro’s telehealth platform on Wednesday, giving patients another way to access a more affordable version of the shot.
Patients could previously only get vials of Zepbound, typically sold in an autoinjector pen, through Lilly’s direct-to-consumer site, LillyDirect. To bolster supplies of the wildly popular medicines amid a nationwide shortage and to offer a more affordable option to patients whose insurance plans don’t cover the drugs, the company launched the vials in August.
